BioInvent Antibody Shows Encouraging Activity with Keytruda in Ovarian Cancer

BioInvent International’s lead immuno-oncology candidate, BI-1808, has shown encouraging results in recurrent ovarian cancer when combined with MSD’s Keytruda (pembrolizumab). In the Phase IIa KEYNOTE-D20 study, the combination achieved an overall response rate (ORR) of 24%, with 65% of patients experiencing disease control. This compares favorably with the 7%–10% ORR previously reported for Keytruda alone.

Among patients with disease control, four achieved partial responses and seven had stable disease, with some responses lasting longer than eight months. All patients had progressed after platinum-based chemotherapy. BioInvent said the activity was observed in both clear cell and high-grade serous ovarian cancer subtypes, suggesting broad potential.

The TNFR2-targeting antibody plus Keytruda was reported to be well tolerated, though detailed safety data have not yet been released. BioInvent plans a Phase IIa expansion study in 20 additional patients, with results expected in the second half of 2026.

08-01-2026